You are viewing the site in preview mode
Skip to main content
| |
Total participants evaluated (n = 340)
|
TS antigen negative participants (n = 297)
|
TS antigen positive participants (n = 43)
|
P
|
|---|
|
Features at presentation
|
n (%)
|
n (%)
|
n (%)
| |
|
Male sex
|
159 (46.8)
|
137 (46.1)
|
22 (51.2)
|
0.5
|
|
Female sex
|
181 (53.2)
|
160 (53.8)
|
21 (48.8)
|
0.5
|
|
Age > 20 years
|
270 (79.4)
|
231 (77.8)
|
39 (90.7)
|
0.05
|
|
Prior contact with primary care facility
|
159 (46.8)
|
141 (47.5)
|
18 (41.9)
|
0.4
|
|
Neurological symptoms > two weeks
|
190 (55.9)
|
168 (56.6)
|
22 (51.2)
|
0.5
|
|
Fever reported/documented
|
99 (29.1)
|
89 (30.0)
|
10 (23.3)
|
0.3
|
|
Severe headache
|
156 (45.9)
|
136 (45.8)
|
20 (46.5)
|
0.9
|
|
Severe headache without fever
|
101 (29.7)
|
86 (29.0)
|
15 (34.9)
|
0.4
|
|
Gait/walking disorders
|
97 (28.5)
|
86 (29.0)
|
11 (25.6)
|
0.6
|
|
Seizure
|
84 (24.7)
|
73 (24.6)
|
11 (25.6)
|
0.8
|
|
Focal sensory-motor deficit
|
77 (22.6)
|
67 (22.6)
|
10 (23.3)
|
0.9
|
|
Cognitive and/or behavior disturbance
|
72 (21.2)
|
60 (20.2)
|
12 (27.9)
|
0.2
|
|
Altered state of consciousness
|
69 (20.3)
|
61 (20.5)
|
8 (18.6)
|
0.7
|
|
Final diagnoses
|
n (%)
|
n (%)
|
n (%)
| |
|
Confirmed targeted infections
|
84 (24.7)
|
76 (25.6)
|
8 (18.6)
|
0.3
|
|
Confirmed and suspected infections
|
119 (35.0)
|
107 (36.0)
|
12 (27.9)
|
0.2
|
|
Non-communicable conditions
|
156 (45.9)
|
134 (45.1)
|
22 (51.2)
|
0.4
|
|
Epilepsy
|
60 (17.6)
|
51 (17.2)
|
9 (20.9)
|
0.5
|
|
Psychiatric disorders
|
53 (15.6)
|
47 (15.8)
|
6 (14.0)
|
0.7
|
|
Myelo-radiculo-neuropathic syndromes
|
37 (10.9)
|
30 (10.1)
|
7 (16.3)
|
0.2
|
|
Cerebrovascular accident
|
23 (6.8)
|
20 (6.7)
|
3 (7.0)
|
0.9
|
|
Outcome
|
n (%)
|
n (%)
|
n (%)
| |
|
Death
|
26 (7.6)
|
23 (7.7)
|
3 (7.0)
|
0.8
|
